Research programme: anti-dengue virus therapeutics - Astellas Pharma/Nagasaki University
Latest Information Update: 06 Apr 2016
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Nagasaki University School of Medicine
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dengue
Most Recent Events
- 01 Apr 2016 Discontinued for Dengue in Japan (unspecified route)
- 21 Mar 2013 Early research in Dengue in Japan (unspecified route)